In this edition, I'm releasing a full equity research report on Clorox — a Consumer Staples name most investors have written off as a slow-moving dividend stock, but where the current setup is considerably more interesting than the surface-level numbers suggest.
This report breaks down the initiation at BUY, the case for a recovery in normalized earnings, and the structural argument for building a position at a price level that reflects peak pessimism rather than fundamental impairment....